Structure Therapeutics reports new data on oral amylin and GLP-1 obesity drugsSep 8Clinical readoutaleniglipronStructure Therapeutics Inc.
Structure Therapeutics doses first patients in Phase 3 obesity program for aleniglipronAug 6Quarterly updatealeniglipronStructure Therapeutics Inc.
Sign inSign in